Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Picibanil × Clear all
NCT00010452 2015-03-25

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

FDA Office of Orphan Products Development

Phase 2/3 Completed
150 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon âš¡